Image de couverture de livre

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Hematological Oncology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
par: Giacomo Loseto, et autres
Publié: (2025)

Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
par: Tom Schlusemann, et autres
Publié: (2026)

57 | CLONAL HEMATOPOIESIS IN FOLLICULAR LYMPHOMA: ANALYSIS OF THE PHASE III FIL FOLL12 TRIAL
par: R. Moia, et autres
Publié: (2025)

Characterizing second line and beyond therapies for primary central nervous system lymphomas
par: Brian Primeaux, et autres
Publié: (2024)

Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
par: Alessandra Iurlo, et autres
Publié: (2025)

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab
par: Livia Donzelli, et autres
Publié: (2025)

Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD
par: Carmen Martínez, et autres
Publié: (2024)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
par: Vittorio Ruggero Zilioli, et autres
Publié: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
par: Hidehiro Itonaga, et autres
Publié: (2024)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
par: Ganggang Wang, et autres
Publié: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
par: Dong Liang, et autres
Publié: (2025)

Real World Incidence and Etiology of Infectious Complications in Adults With Ph‐Negative Acute Lymphoblastic Leukemia Treated With the Pediatric‐Inspired GIMEMA LAL1913 Program. A Campus All Study
par: Patrizia Zappasodi, et autres
Publié: (2025)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
par: Beatrice Casadei, et autres
Publié: (2024)

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
par: Ernesto Vigna, et autres
Publié: (2025)

52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
par: C. Thieblemont, et autres
Publié: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
par: Gabriela Forestieri, et autres
Publié: (2024)

Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement
par: Elisabetta M. Abenavoli, et autres
Publié: (2024)

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager
par: Daniele Caracciolo, et autres
Publié: (2026)

360 | BENDAMUSTINE SUPERCHARGE PLUS BRENTUXIMAB VEDOTIN AS EARLY SALVAGE FOLLOWING FAILURE OF 2 ABVD CYCLES IN HL: LONG‐TERM RESULTS OF A RETROSPECTIVE MULTICENTER STUDY
par: C. Giordano, et autres
Publié: (2025)

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
par: M. Delia, et autres
Publié: (2025)

Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
par: Idanna Innocenti, et autres
Publié: (2025)

Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
par: Evgenia Verrou, et autres
Publié: (2024)

CEBPA ‐bZIP Mutations in AML Patients Treated With Non‐Intensive Therapy: A Study by the Spanish PETHEMA Registry
par: Esther Prados de la Torre, et autres
Publié: (2026)

Efferocytosis and M2 Macrophage Polarization Gene Expression Correlates With Relapsed and Refractory Classical Hodgkin Lymphoma Patients: A Multi‐Omic Analysis
par: Juan Quarroz Braghini, et autres
Publié: (2025)

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma
par: Sara Ovejero, et autres
Publié: (2025)

Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
par: Doriana Gramegna, et autres
Publié: (2026)

Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial
par: Paula de Melo Campos, et autres
Publié: (2025)

Implications of Genetic, Biological and Clinical Parameters in Patients With Richter Syndrome: A Monocentric Experience
par: Idanna Innocenti, et autres
Publié: (2024)

Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
par: M. Picardi, et autres
Publié: (2024)

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study
par: Enrica Antonia Martino, et autres
Publié: (2025)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
par: Alberto Bavieri, et autres
Publié: (2025)

CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia
par: Marilisa Galasso, et autres
Publié: (2024)

New insights into the Bortezomib‐induced cytotoxic and resistance mechanisms in a primary effusion lymphoma mouse model
par: Maria Anele Romeo, et autres
Publié: (2024)

Re: Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
par: Theodoros P. Vassilakopoulos, et autres
Publié: (2025)

FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia
par: María Turos‐Cabal, et autres
Publié: (2024)

862 | RADIOTHERAPY AS A CAR‐T BRIDGING STRATEGY FOR PATIENTS WITH LARGE B‐CELL LYMPHOMA: A SOUTH WALES EXPERIENCE
par: G. Edwards, et autres
Publié: (2025)

543 | OBINUTUZUMAB‐INDUCED ADCC AS A PREDICTOR OF MINIMAL RESIDUAL DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A PRELIMINARY STUDY
par: R. García‐Muñoz, et autres
Publié: (2025)

840 | CLL‐RT1 EXTENSION TRIAL: ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD1 INHIBITOR, PLUS SONROTOCLAX, A BCL2 INHIBITOR, FOR TREATMENT OF RICHTER TRANSFORMATION
par: O. Al‐Sawaf, et autres
Publié: (2025)

696 | OUTCOME DISPARITIES IN PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS AT AN ACADEMIC CENTER WITH A PREDOMINANTLY HISPANIC PATIENT POPULATION
par: Y. Teklie, et autres
Publié: (2025)

One Grammar, Many Labels: Revisiting the Continuum of Myeloid Neoplasms
par: Francesco Tarantini, et autres
Publié: (2026)